Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00984035 · ClinicalTrials.gov registry record
Investigation of Cisplatin-Related Kidney Toxicity
A clinical trial of Cancer, sponsored by University of Chicago.
- Completed
- Registry status
- 102
- Enrollment target
- 1
- Study location
NCT00984035: Completed study of Cancer, sponsored by University of Chicago.
NCT00984035 is a study of Cancer that has completed, run by University of Chicago. The registered enrollment target is 102 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00984035, a study of Cancer, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to identify novel biomarkers of kidney injury in patients receiving cisplatin. This study will also collect DNA for future analysis.
Conditions Studied
Interventions
- OTHER urine samples (biomarkers)
- OTHER blood samples (biomarkers)
- OTHER blood sample (DNA)
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2009-09-22 |
| Est. Completion | 2018-03 |
What the finished NCT00984035 record still lists
NCT00984035 is an observational study that tracks outcomes without assigning an intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which urine samples (biomarkers) is the first listed.
NCT00984035 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00984035 about?
NCT00984035 is a clinical study titled "Investigation of Cisplatin-Related Kidney Toxicity". The purpose of this study is to identify novel biomarkers of kidney injury in patients receiving cisplatin. This study will also collect DNA for future analysis.
What is the current status of trial NCT00984035?
This trial is currently completed. The enrollment target is 102 participants. The study started on 2009-09-22. Estimated completion is 2018-03.
What conditions does trial NCT00984035 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT00984035?
The interventions under investigation include: urine samples (biomarkers) (OTHER), blood samples (biomarkers) (OTHER), blood sample (DNA) (OTHER).
Who is sponsoring clinical trial NCT00984035?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00984035 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00984035's enrollment target sits among peer trials
102 311th of 615 higher than 304 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI